EBSCN·2024-08-27 02:03Investment Rating - The report maintains a "Buy" rating for the company [3]. Core Insights - The company achieved a revenue of 13.6 billion yuan in the first half of 2024, representing a year-on-year increase of 21.8%, and a net profit of 3.43 billion yuan, up 48.7% year-on-year [2][3]. - The innovative drug business generated 6.612 billion yuan in revenue, a growth of 33% year-on-year, while the generic drug business saw a slight decline due to centralized procurement impacts [3]. - The company confirmed a 160 million euro upfront payment from Merck Healthcare as revenue, indicating recognition of its innovation capabilities by international pharmaceutical companies [3]. Revenue and Profit Forecast - The company is projected to achieve net profits of 6.023 billion yuan, 7.233 billion yuan, and 8.591 billion yuan for the years 2024, 2025, and 2026 respectively, with upward adjustments of 16.6%, 16.3%, and 15.3% [3][4]. - The current price-to-earnings (P/E) ratios are forecasted to be 46, 38, and 32 for the years 2024, 2025, and 2026 respectively [4][10]. International Expansion - The company is actively pursuing internationalization by licensing its GLP-1 class innovative drugs to Hercules in the U.S. for approximately 6 billion USD, while also acquiring a 19.9% equity stake in Hercules [3]. - The company is conducting multiple overseas clinical trials, with three ADC products receiving fast-track designation from the U.S. FDA in the first half of 2024 [3]. Financial Metrics - The company’s revenue is expected to grow from 27.221 billion yuan in 2024 to 34.681 billion yuan in 2026, with a compound annual growth rate (CAGR) of approximately 15.72% [4][7]. - The gross profit margin is projected to improve from 84.6% in 2023 to 85.9% in 2026 [9].